194 related articles for article (PubMed ID: 34959252)
21. The epidemiology of Waldenström macroglobulinemia.
McMaster ML
Semin Hematol; 2023 Mar; 60(2):65-72. PubMed ID: 37099032
[TBL] [Abstract][Full Text] [Related]
22. [Lymphoplasmacytic lymphoma: a clinicopathological and prognostic analysis of 27 cases].
Chen Y; Zhang F; Wu HM; Luo XL; Zhang KP; Liu YH
Zhonghua Bing Li Xue Za Zhi; 2021 Dec; 50(12):1346-1352. PubMed ID: 34865422
[No Abstract] [Full Text] [Related]
23. Waldenstrom macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients.
Lin P; Bueso-Ramos C; Wilson CS; Mansoor A; Medeiros LJ
Am J Surg Pathol; 2003 Aug; 27(8):1104-13. PubMed ID: 12883242
[TBL] [Abstract][Full Text] [Related]
24. Prognostic factors and primary treatment for Waldenström macroglobulinemia - a Swedish Lymphoma Registry study.
Brandefors L; Melin B; Lindh J; Lundqvist K; Kimby E
Br J Haematol; 2018 Nov; 183(4):564-577. PubMed ID: 30198549
[TBL] [Abstract][Full Text] [Related]
25. Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Kobayashi H; Asada N; Egusa Y; Ikeda T; Sakamoto M; Abe M; Ennishi D; Sakata M; Takaki A; Kawahara S; Meguri Y; Nishimori H; Fujii N; Matsuoka KI; Sato Y; Yoshino T; Maeda Y
Int J Hematol; 2021 Sep; 114(3):401-407. PubMed ID: 33907976
[TBL] [Abstract][Full Text] [Related]
26. Familial aggregation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with solid tumors and myeloid malignancies.
Kristinsson SY; Goldin LR; Turesson I; Björkholm M; Landgren O
Acta Haematol; 2012; 127(3):173-7. PubMed ID: 22310551
[TBL] [Abstract][Full Text] [Related]
27. Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.
Naderi N; Yang DT
Arch Pathol Lab Med; 2013 Apr; 137(4):580-5. PubMed ID: 23544948
[TBL] [Abstract][Full Text] [Related]
28. [Waldenström macroglobulinemia: Japanese perception].
Sekiguchi N
Rinsho Ketsueki; 2019; 60(8):988-997. PubMed ID: 31484900
[TBL] [Abstract][Full Text] [Related]
29. Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016.
Dalal NH; Dores GM; Curtis RE; Linet MS; Morton LM
Br J Haematol; 2020 Jun; 189(6):1107-1118. PubMed ID: 32090327
[TBL] [Abstract][Full Text] [Related]
30. Familial Waldenstrom's macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies--A population-based study from northern Sweden.
Brandefors L; Kimby E; Lundqvist K; Melin B; Lindh J
Acta Oncol; 2016; 55(1):91-8. PubMed ID: 26559865
[TBL] [Abstract][Full Text] [Related]
31. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG).
Buske C; Hoster E; Dreyling M; Eimermacher H; Wandt H; Metzner B; Fuchs R; Bittenbring J; Woermann B; Hohloch K; Hess G; Ludwig WD; Schimke J; Schmitz S; Kneba M; Reiser M; Graeven U; Klapper W; Unterhalt M; Hiddemann W;
Leukemia; 2009 Jan; 23(1):153-61. PubMed ID: 18818699
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression.
Cao X; Medeiros LJ; Xia Y; Wang X; Thomas SK; Loghavi S; Li X; Shah JJ; Gustafson SA; Weber DM; Miranda RN; Xu-Monette ZY; Orlowski RZ; Young KH
Leuk Lymphoma; 2016 May; 57(5):1104-13. PubMed ID: 26421453
[TBL] [Abstract][Full Text] [Related]
33. [Lymphoplasmacytic lymphoma with Waldenström's macroglobulinemia: a clinicopathological and immunophenotypic study of 40 Chinese patients].
Liang DN; Li GD; Dai L; Huang J; Wang WY; Feng WH; Li FY; Liao DY
Zhonghua Bing Li Xue Za Zhi; 2009 Nov; 38(11):728-32. PubMed ID: 20079010
[TBL] [Abstract][Full Text] [Related]
34.
Luo Y; Cao X; Pan Q; Li J; Feng J; Li F
J Nucl Med; 2019 Dec; 60(12):1724-1729. PubMed ID: 31101745
[No Abstract] [Full Text] [Related]
35. Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.
Vajdic CM; Landgren O; McMaster ML; Slager SL; Brooks-Wilson A; Smith A; Staines A; Dogan A; Ansell SM; Sampson JN; Morton LM; Linet MS
J Natl Cancer Inst Monogr; 2014 Aug; 2014(48):87-97. PubMed ID: 25174029
[TBL] [Abstract][Full Text] [Related]
36. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.
Treon SP; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Sheehy P; Manning RJ; Patterson CJ; Tripsas C; Arcaini L; Pinkus GS; Rodig SJ; Sohani AR; Harris NL; Laramie JM; Skifter DA; Lincoln SE; Hunter ZR
N Engl J Med; 2012 Aug; 367(9):826-33. PubMed ID: 22931316
[TBL] [Abstract][Full Text] [Related]
37. Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders.
Pangalis GA; Kyrtsonis MC; Kontopidou FN; Vassilakopoulos TP; Siakantaris MP; Dimopoulou MN; Kittas C; Angelopoulou MK
Semin Oncol; 2003 Apr; 30(2):201-5. PubMed ID: 12720136
[TBL] [Abstract][Full Text] [Related]
38. Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis.
Wang W; Lin P
Pathology; 2020 Jan; 52(1):6-14. PubMed ID: 31767130
[TBL] [Abstract][Full Text] [Related]
39. Community-acquired infections associated with increased risk of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia.
McShane CM; Murray LJ; Engels EA; Anderson LA
Br J Haematol; 2014 Mar; 164(5):653-8. PubMed ID: 24528127
[TBL] [Abstract][Full Text] [Related]
40. Lymphoplasmacytic Lymphoma with Only Lambda Light Chain Monoclonal Paraprotein Expression.
Cautha S; Gupta S; Hanif A; Moirangthem V; Jain K
Eur J Case Rep Intern Med; 2022; 9(2):003106. PubMed ID: 35265542
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
